Background: The Guillain-Barré syndrome (GBS) occurs after infections and as an adverse reaction to vaccines. No detailed information on incidence rates (IRs) in Germany is available. Methods: This retrospective cohort study estimated age- and sex-specific IRs of GBS in Germany in the years 2007-2009 based on electronic healthcare data from the German Pharmacoepidemiological Research Database (GePaRD). Two case definitions were applied. GBS cases had a main discharge diagnosis of GBS. GBS_PROCEDURE cases in addition had codes for relevant diagnostic procedures. Crude and standardized IRs (SIRs) with 95% confidence intervals were stratified by year, age group, sex, region and season. IR ratios (IRRs) for each stratification factor were calculated by multivariable Poisson regression. Results: Among 13,297,678 persons, 889 (693) incident GBS (GBS_PROCEDURE) cases were identified. Overall SIRs per 100,000 person years were 2.4 (2.2-2.5) for GBS and 1.8 (1.7-2.0) for GBS_PROCEDURE. (S)IRs increased with age, peaking in the age group 70-79 years (IR GBS: 5.5 (4.7-6.5)) and were higher in males than in females (e.g., IR GBS: IRR = 1.5 (1.3-1.7)) and in February-April, as compared to the rest of the year. No regional pattern was observed. Conclusion: (S)IRs of GBS in Germany differed by age, sex and season and were comparable to those found in other studies. Results might be used as a comparator in vaccine safety monitoring.

Keywords:
Guillain-Barré Syndrome, Polyneuropathy, Vaccine safety, Administrative data
1.
Yuki N, Hartung HP: Guillain-Barre syndrome. N Engl J Med 2012;366:2294-2304.
2.
Hughes RA, Cornblath DR: Guillain-Barre syndrome. Lancet 2005;366:1653-1666.
3.
Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al: Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 2001;56:758-765.
4.
Hartung HP, Keller-Stanislawski B, Hughes RA, Lehmann HC: [Guillain-Barre syndrome after exposure to influenza]. Nervenarzt 2012;83:714-730.
5.
Jacobs BC, Rothbarth PH, van der Meche FG, Herbrink P, Schmitz PI, de Klerk MA, et al: The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998;51:1110-1115.
6.
Kang JH, Sheu JJ, Lin HC: Increased risk of Guillain-Barre Syndrome following recent herpes zoster: a population-based study across Taiwan. Clin Infect Dis 2010;51:525-530.
7.
Poropatich KO, Walker CL, Black RE: Quantifying the association between Campylobacter infection and Guillain-Barre syndrome: a systematic review. J Health Popul Nutr 2010;28:545-552.
8.
Sivadon-Tardy V, Orlikowski D, Porcher R, Sharshar T, Durand MC, Enouf V, et al: Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis 2009;48:48-56.
9.
Winner SJ, Evans JG: Age-specific incidence of Guillain-Barre syndrome in Oxfordshire. Q J Med 1990;77:1297-1304.
10.
Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F: Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 2011;343:d5956.
11.
De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, et al: Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012;308:175-181.
12.
Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M: Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011;343:d3908.
13.
Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al: Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011;29:8279-8284.
14.
Nelson KE: Invited commentary: influenza vaccine and Guillain-Barre syndrome - is there a risk? Am J Epidemiol 2012;175:1129-1132.
15.
Paul Ehrlich Institut: Zusammenhang zwischen pandemischer Influenza A/H1N1v-Impfung und Guillain-Barré-Syndrom/Miller-Fisher-Syndrom in Deutschland. http://www.pei.de/cln_101/nn_2248804/DE/arzneimittelsicherheit-vigilanz/pharmakovigilanz/forschung/gbs-studie/gbs-guillan-barre-syndrom-studie-node.html?__nnn=true#doc2338784bodyText3 (accessed June 26, 2014).
16.
Souayah N, Nasar A, Suri MF, Qureshi AI: Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 2007;25:5253-5255.
17.
Souayah N, Nasar A, Suri MF, Qureshi AI: Guillain-Barre syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005). J Clin Neuromuscul Dis 2009;11:1-6.
18.
Souayah N, Michas-Martin PA, Nasar A, Krivitskaya N, Yacoub HA, Khan H, et al: Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine 2011;29:886-889.
19.
Tokars JI, Lewis P, Destefano F, Wise M, Viray M, Morgan O, et al: The risk of Guillain-Barre syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf 2012;21:546-552.
20.
Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, et al: Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf 2012;21:1350-1358.
21.
Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, Connor W, et al: Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am J Epidemiol 2012;175:1110-1119.
22.
Sejvar JJ, Baughman AL, Wise M, Morgan OW: Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36:123-133.
23.
Lehmann HC, Kohne A, Meyer zu Horste G, Kieseier BC: Incidence of Guillain-Barre syndrome in Germany. J Peripher Nerv Syst 2007;12:285.
24.
Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B, et al: Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-2122.
25.
Garbe E, Suling M, Kloss S, Lindemann C, Schmid U: Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf 2011;20:258-264.
26.
Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E: Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010;10:360.
27.
Lindemann C, Langner I, Kraut AA, Banaschewski T, Schad-Hansjosten T, Petermann U, et al: Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany. J Child Adolesc Psychopharmacol 2012;22:307-314.
28.
Pigeot I, Ahrens W: Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 2008;17:215-223.
29.
Daly LE: Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998;147:783-790.
30.
Gesundheitsberichterstattung des Bundes. Standardbevölkerung. http://www.gbe-bund.de (accessed June 26, 2014).
31.
Rasmussen TA, Jorgensen MR, Bjerrum S, Jensen-Fangel S, Stovring H, Ostergaard L, et al: Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. BMJ 2012;345:e5823.
32.
McLean M, Duclos P, Jacob P, Humphreys P: Incidence of Guillain-Barre syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology 1994;5:443-448.
33.
Criteria for diagnosis of Guillain-Barre syndrome. Ann Neurol 1978;3:565-566.
34.
Asbury AK, Cornblath DR: Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990;27(suppl):S21-S24.
35.
Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al: Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29:599-612.
36.
Funch D, Holick C, Velentgas P, Clifford R, Wahl PM, McMahill-Walraven C, et al: Algorithms for identification of Guillain-Barre Syndrome among adolescents in claims databases. Vaccine 2013;31:2075-2079.
37.
van der Maas NA, Kramer MA, Jacobs BC, van Soest EM, Dieleman JP, Kemmeren JM, et al: Guillain-Barre syndrome: background incidence rates in The Netherlands. J Peripher Nerv Syst 2011;16:243-249.
38.
Arbeitsgemeinschaft Influenza: Abschlussbericht der Influenzasaison 2006/2007. Robert Koch Institut, 2007.
39.
Arbeitsgemeinschaft Influenza: Abschlussbericht der Influenzasaison 2007/2008. Robert Koch Institut, 2008.
40.
Arbeitsgemeinschaft Influenza: Abschlussbericht der Influenzasaison 2008/2009. Robert Koch Institut, 2009.
41.
Epidemiologisches Bulletin 21/2010: Rückblick: Epidemiologie und Infektionsschutz im zeitlichen Verlauf der Influenzapandemie (H1N1) 2009 Robert Koch Institut. http://www.rki.de/DE/Content/InfAZ/I/Influenza/Pandemie/Pandemie_Node.html (accessed June 26, 2014).
42.
Frenzen PD: Economic cost of Guillain-Barre syndrome in the United States. Neurology 2008;71:21-27.
43.
Korinthenberg R, Gold R, Felderhoff-Müser U: Leitlinie der Gesellschaft für Neuropädiatrie: Guillain-Barré Syndrom im Kindes-und Jugendalter. http://www.awmf.org/leitlinien/detail/ll/022-008.html (accessed June 26, 2014).
44.
Rees JH, Hughes RA: Campylobacter jejuni infection and childhood Guillain-Barre syndrome. Ann Neurol 1994;35:248-249.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.